vialaudit
PEPTIDE GUIDE · 10 MIN·UPDATED 2026-11-12·BY SARA VANCE

KLOW peptide: what 58 public lab results show, plus GLOW

KLOW is GHK-Cu, BPC-157, TB-500 and KPV in one vial; GLOW drops KPV. In 58 KLOW and 41 GLOW lab results: median fill 108.7% and 107.9%, one identity fail each.

QUICK ANSWER

KLOW is a pre-mixed research-peptide blend sold under one name: GHK-Cu, BPC-157, TB-500 and KPV in one vial. GLOW is the same blend without KPV (GHK-Cu, BPC-157, TB-500). No published trial has tested either combination. On the public lab record we pooled, 58 KLOW results from 54 clients had a median fill of 108.7% of label and median HPLC purity of 99.80%; 41 GLOW results from 39 clients had 107.9% and 99.79%. Each blend has one explicit fail, and in both cases the lab could not confirm the blend's identity.

KLOW is a four-peptide blend — GHK-Cu, BPC-157, TB-500 and KPV — sold pre-mixed in one vial. GLOW is the same blend without KPV. On the public lab record, both mostly arrive as labelled: 58 KLOW results had a median fill of 108.7% of label and 41 GLOW results 107.9%, at a median HPLC purity of 99.80% and 99.79%. Each blend has exactly one explicit fail, and in both cases the lab could not confirm what was in the vial. No published trial has tested either combination.

What the lab records show for KLOW and GLOW

We pooled public certificates from two lab-run databases (Kovera Labs and Janoshik) and two vendor certificate pages (Ascension Peptides and Injectify), removed duplicate copies of the same test, and counted each blend separately. Most results are Kovera certificates.

BlendResultsClientsMedian fillUnder 90%Over 110%Median purityExplicit fails
KLOW5854108.7%3.9% (2 of 51)25.5% (13 of 51)99.80% (lowest 99.36%)1
GLOW4139107.9%2.7% (1 of 37)27.0% (10 of 37)99.79% (lowest 99.64%)1

Fill is measured content as a share of the label. Percentages are of results that print a fill figure (51 for KLOW, 37 for GLOW). KLOW records are dated 29 September 2025 to 29 May 2026; GLOW records 30 June 2025 to 23 May 2026. The full per-compound table, including the single-peptide figures, is in our 2,087-result purity and fill study.

Fill on a blend is one number for four peptides. Kovera prints a "Blend Avg Net Content" figure for the whole vial and a component table beneath it. A vial can hit 100% of label while one component is short and another is long. The headline fill tells you the vial is not empty. Only the component table tells you the ratio. Against single peptides the blends run slightly leaner: the median across all 2,087 results is 109.6%, with 47.6% of vials over 110%, against about a quarter for KLOW and GLOW.

Identity is harder to verify on a blend. A single-peptide certificate confirms one molecule. A blend certificate has to confirm three or four. Both fails are cases where it could not:

  • TTX EDGE, Klow, Kovera report KVR-2026-5953A8, analysed 19 May 2026. Net content 24.82 mg against an 80 mg label (31.0%). Purity 99.81%. The blend identification line reads "Unknown", and Kovera marks it a fail.
  • Glacier Aminos, Glow, Kovera report KVR-2026-50085D, analysed 17 May 2026. Net content 51.01 mg against a 70 mg label (72.9%). Purity 99.91%. The component table prints GHK-Cu at 51.01 mg and BPC-157 and TB-500 at zero, with identity "Unknown". (What the full Glacier record shows.)

Both vials scored above 99.8% purity. HPLC purity is the share of the chromatogram that sits in the expected peaks; it says nothing about whether all three or four peptides are there. On the Glacier certificate, a vial that appears to hold only GHK-Cu still reads 99.91% pure. Both fails also fall inside one window: all 11 identity fails in our 1,828-certificate Kovera mirror are dated 11 to 22 May 2026. The fails stand, but two from one fortnight are not yet a vendor pattern.

The second KLOW result under 90% is not a fail. Axon Peptide's KLOW Blend, Kovera report KVR-2026-F5110B (20 May 2026), measured 21.79 mg against an 80 mg label, 27.2%, with each of the four components between 5.13 and 5.79 mg and identity confirmed. Kovera marks net content as a pass against a specification printed as "~80mg". If you are reading a blend certificate, read the milligrams, not only the pass column.

A regulator found no TB-500 in two KLOW products. On 5 November 2026 Australia's TGA reported "No TB-500 detected" in Synedica KLOW 80 mg and Synedica BARBIE KLOW 100 mg, a brand that does not appear in the certificates we mirror (what the TGA and Health Canada found).

Blend names move. On 3 November 2026 Kovera re-published certificate KVR-2026-09FFFA under the product name "Wolverine Blend". Our August mirror lists the same certificate, same lot, as "BPC-157/TB-500". The certificate number and lot did not change. Search the report number, not the product name.

What is in KLOW and GLOW

No standard defines either blend. The composition comes from how sellers and labs name the vials:

BlendComponents on the recordExample listing
KLOWGHK-Cu, BPC-157, TB-500, KPVJanoshik category "KLOW (GHK or GHK-Cu/ TB-500/ BPC-157/ KPV)"; Ascension "KLOW (GHK-Cu, BPC-157, Thymosin beta4, KPV)"
GLOWGHK-Cu, BPC-157, TB-500Janoshik sample "GLOW 70 (BPC-157, TB500, GHK-Cu)"; Ascension "GLOW (GHK-Cu, BPC-157, Thymosin B4)"

There is no pharmacopoeia entry for either name, so there is no fixed ratio. Each seller sets its own, and the label usually prints only a total.

The four components

GHK-Cu, the copper tripeptide

GHK-Cu (glycyl-histidyl-lysine bound to copper) is the most-studied of the four in the dermal literature. Pickart's 2008 review (PMID 18644225) summarises four decades of work on collagen synthesis, antioxidant signalling and wound contraction. Most of that evidence is cell, animal or topical. See the GHK-Cu peptide page.

BPC-157, the gastric pentadecapeptide

BPC-157 is a fifteen-residue synthetic fragment of a protein found in human gastric juice. Its literature is almost entirely rodent work on tendon, ligament and gut repair, much of it from one research group in Zagreb. It is not approved for any human indication anywhere. See the BPC-157 page.

TB-500, the thymosin beta-4 fragment

TB-500 is sold as a synthetic fragment of thymosin beta-4, though vendor products do not always agree on which fragment. Thymosin beta-4 binds G-actin and affects cell migration; preclinical work covers cardiac repair (Bock-Marquette 2004, PMID 15565145) and corneal healing. No Phase 3 trial has reported. See the TB-500 page and the BPC-157 and TB-500 stack read.

KPV, the alpha-MSH tripeptide

KPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. In mouse colitis models it is taken up by the PepT1 transporter and lowers NF-kB-driven inflammatory signalling (Dalmasso 2008, PMID 18061177). There are no registered human trials. KPV is the only difference between KLOW and GLOW. See the KPV page.

What the literature shows about the combination

No published peer-reviewed trial has tested KLOW or GLOW. A PubMed search for GHK-Cu with BPC-157, TB-500 and KPV together returns nothing. The evidence is single-compound and mostly preclinical:

  • GHK-Cu in dermal wound healing and collagen synthesis (Pickart 2008, PMID 18644225)
  • BPC-157 in rodent tendon and gut models (Sikiric et al., preclinical reviews)
  • Thymosin beta-4 in cardiac and corneal repair (Bock-Marquette 2004, PMID 15565145)
  • KPV in mouse colitis via PepT1 (Dalmasso 2008, PMID 18061177)

The case sellers make for the blend is mechanism complementarity: matrix deposition, angiogenesis, actin dynamics and cytokine signalling are distinct layers of the textbook repair response. The argument holds together on paper. It is not evidence that the four together do anything different from one of them alone.

Three things no study has measured:

  1. Outcome data in one defined indication, against placebo and against each component alone.
  2. Stability in the vial. GHK-Cu brings copper into a solution shared with two or three other peptides. No stability study of the mixed blend is published.
  3. Combined safety data. Each component has a thin single-compound safety record. There is no blend-level record at all.

Until that work exists, KLOW and GLOW are product names, not researched combinations.

Where KLOW and GLOW stand legally

None of the four components is an FDA-approved drug. On 28 October 2026 HHS filed an enforcement-discretion policy: it says it will not act against licensed 503A pharmacies compounding six peptides, including BPC-157, TB-500 and KPV, against a prescription and under ten conditions. Condition 7 is one active ingredient only. A KLOW or GLOW vial is a blend, so it falls outside the policy even though BPC-157, TB-500 or KPV alone could qualify. HHS gives adverse-event attribution as the reason. The detail is in our HHS peptide compounding policy explainer.

GHK-Cu is not one of the six. FDA's interim categories split it by route: non-injectable GHK-Cu is in Category 1, injectable GHK-Cu is not eligible, and the advisory committee is due to review it by the end of February 2027.

The policy does not cover research-use-only sales, which is where every KLOW and GLOW vial on the lab record above comes from. Per-compound federal status, with sources, is in our peptide legality checker. This is a summary of public records, not legal advice.

How to read a KLOW or GLOW certificate

  1. Find the component table. A blend certificate that prints only a total and a purity has not shown you the ratio.
  2. Check every component is above zero. The Glacier fail reads 99.91% pure with two of three components at zero.
  3. Read the identity line. "Unknown" is a fail, whatever the purity says.
  4. Match the lot. A certificate describes one lot. If the lot on your vial differs, the certificate is not about your vial.
  5. Search the report number on the lab's own verify page, not the product name, since names change after issue.

What we read, and what we did not

We read the KLOW and GLOW rows of our pooled lab-result table (2,087 de-duplicated results from six sources, built October 2026), the underlying Kovera certificates in our 2 August 2026 mirror and its 3 November 2026 refresh, Janoshik's public listing as mirrored on 30 June 2026, and the certificate pages of Ascension Peptides and Injectify read in May 2026. We read the HHS policy as filed on 28 October 2026. We did not order or test any vial, and we did not read Finnrick for this page. Lab results describe the tested lot only.

Frequently asked

What is in the KLOW blend?

Four peptides in one vial: GHK-Cu, BPC-157, TB-500 and KPV. That is how vendor certificate pages and lab listings name it, for example Janoshik's category line "KLOW (GHK or GHK-Cu/ TB-500/ BPC-157/ KPV)" and Ascension Peptides' certificate listing "KLOW (GHK-Cu, BPC-157, Thymosin beta4, KPV)". An earlier version of this page listed alpha-lipoic acid as a component. No lab record we hold shows lipoic acid in a KLOW vial.

Is KLOW the same as GLOW?

No. GLOW is three peptides, GHK-Cu, BPC-157 and TB-500. KLOW is the same three plus KPV. On the public lab record the two blends look alike: 108.7% versus 107.9% median fill, 99.80% versus 99.79% median purity, one identity fail each.

What do lab results show for KLOW?

Across 58 de-duplicated public results from 54 clients, dated September 2025 to May 2026, the median vial held 108.7% of its label and median HPLC purity was 99.80% (lowest 99.36%). 2 of 51 results with a fill figure were under 90% of label. One certificate failed outright: TTX EDGE's Klow, Kovera report KVR-2026-5953A8, where the blend identification line reads "Unknown".

Is KLOW legal?

KLOW and GLOW are not approved drugs, and none of their four components is FDA-approved. HHS's 28 October 2026 enforcement-discretion policy covers licensed 503A pharmacies compounding BPC-157, TB-500 or KPV against a prescription, but only as single ingredients: condition 7 allows one active ingredient, so a blend is outside it. GHK-Cu is not one of the policy's six peptides. Research-use-only sales are not covered either. This is a summary of public records, not legal advice.

More from the desk

ALL ARTICLES →
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH